D Policy

LONDON - The Thatcher government has decided to scrap existing schemes to help individual companies commercialize their research, in favor of support for a long-term collaborative effort between universities and industries throughout Europe. At the same time it is adding $35 million to the budget of the Department of Trade and Industry for innovative programs, and plans to continue its support for new high tech firms. "The government should not take on responsibilities which are primarily tho

Written byBernard Dixon
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

LONDON - The Thatcher government has decided to scrap existing schemes to help individual companies commercialize their research, in favor of support for a long-term collaborative effort between universities and industries throughout Europe. At the same time it is adding $35 million to the budget of the Department of Trade and Industry for innovative programs, and plans to continue its support for new high tech firms.

"The government should not take on responsibilities which are primarily those of industry," stated a White Paper announcing the changes. "The closer to the marketplace that innovation is taking place, the more fundamental this should be as a guiding principle." The shift in policy does not affect the government's Small Firms Merit Award for Research and Technology (SMART) program. "The rise of new high-technology firms adds an extra element of rivalry and flexibility to the market's response to technology opportunities," The White Paper declared, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies